BACKGROUND: Antiretroviral drugs (ARV), specifically nucleoside analogs, are toxic to mitochondrial oxidative phosphorylation. Other metabolic pathways, such as fatty acid oxidation, organic acid metabolism and amino acid metabolism, are dependent on normal oxidative phosphorylation but remain unexamined as potential points of ARV toxicity. METHODS: We analyzed newborn screening data from New York and compared proportions of abnormal newborn metabolic screens in HIV antibody screen-positive and HIV screen-negative neonates. Subsequently, we compared acylcarnitine levels in ARV-exposed (n = 16) and ARV-unexposed (n = 14) HIV-exposed infants to assess for dysfunctional fatty and organic acid metabolism. RESULTS: : The rate of abnormal newborn metabolic screens in HIV screen-positive infants was higher than that in the general population (2.2% versus 1.2%; P = 0.00025), most of which were for disorders of mitochondria-related metabolism. Abnormal acylcarnitine levels occurred more frequently in ARV-exposed compared with ARV-unexposed infants (43% versus 0%; P = 0.02). CONCLUSIONS: A higher proportion of positive metabolic screens in HIV screen-positive neonates suggests that HIV or ARV exposure is associated with dysfunctional intermediary metabolism in newborns. Abnormal acylcarnitine levels were more frequent in ARV-exposed infants, suggesting that ARV may perturb normal fatty acid oxidation in some infants. Studies designed to validate and determine the clinical significance of these findings are warranted.
BACKGROUND: Antiretroviral drugs (ARV), specifically nucleoside analogs, are toxic to mitochondrial oxidative phosphorylation. Other metabolic pathways, such as fatty acid oxidation, organic acid metabolism and amino acid metabolism, are dependent on normal oxidative phosphorylation but remain unexamined as potential points of ARV toxicity. METHODS: We analyzed newborn screening data from New York and compared proportions of abnormal newborn metabolic screens in HIV antibody screen-positive and HIV screen-negative neonates. Subsequently, we compared acylcarnitine levels in ARV-exposed (n = 16) and ARV-unexposed (n = 14) HIV-exposed infants to assess for dysfunctional fatty and organic acid metabolism. RESULTS: : The rate of abnormal newborn metabolic screens in HIV screen-positive infants was higher than that in the general population (2.2% versus 1.2%; P = 0.00025), most of which were for disorders of mitochondria-related metabolism. Abnormal acylcarnitine levels occurred more frequently in ARV-exposed compared with ARV-unexposed infants (43% versus 0%; P = 0.02). CONCLUSIONS: A higher proportion of positive metabolic screens in HIV screen-positive neonates suggests that HIV or ARV exposure is associated with dysfunctional intermediary metabolism in newborns. Abnormal acylcarnitine levels were more frequent in ARV-exposed infants, suggesting that ARV may perturb normal fatty acid oxidation in some infants. Studies designed to validate and determine the clinical significance of these findings are warranted.
Authors: Jonathan L Slaughter; Jareen Meinzen-Derr; Susan R Rose; Nancy D Leslie; Ram Chandrasekar; Sharon M Linard; Henry T Akinbi Journal: Pediatrics Date: 2010-10-25 Impact factor: 7.124
Authors: Benjamin L Shneider; Piero Rinaldo; Sukru Emre; John Bucuvalas; Robert Squires; Michael Narkewicz; Gabriel Gondolesi; Margret Magid; Raffaella Morotti; Linda S Hynan Journal: Hepatology Date: 2005-04 Impact factor: 17.425
Authors: S Vijay; A Patterson; S Olpin; M J Henderson; S Clark; C Day; G Savill; J H Walter Journal: J Inherit Metab Dis Date: 2006-07-23 Impact factor: 4.982
Authors: Richard H Haas; Sumit Parikh; Marni J Falk; Russell P Saneto; Nicole I Wolf; Niklas Darin; Lee-Jun Wong; Bruce H Cohen; Robert K Naviaux Journal: Mol Genet Metab Date: 2008-02-01 Impact factor: 4.797
Authors: Jennifer Jao; Denise L Jacobson; Wendy Yu; William Borkowsky; Mitchell E Geffner; Elizabeth J McFarland; Kunjal Patel; Paige L Williams; Tracie Miller Journal: J Acquir Immune Defic Syndr Date: 2019-07-01 Impact factor: 3.731
Authors: Jennifer Jao; Kathleen M Powis; Brian Kirmse; Chunli Yu; Fanny Epie; Emmanuel Nshom; Elaine J Abrams; Rhoda S Sperling; Derek Leroith; Mitchell E Geffner; Irwin J Kurland; Hélène C F Côté Journal: AIDS Date: 2017-11-28 Impact factor: 4.177
Authors: Brian Kirmse; Charlotte Hobbs; Lisa Aaron; Grace Montepiedra; Marshall Summar; Paige L Williams; Caitlin J Smith; Russell Van Dyke; Chunli Yu; Kelli K Ryckman; William Borkowsky Journal: Pediatr Infect Dis J Date: 2022-07-13 Impact factor: 3.806
Authors: Samuel S Bailin; Cathy A Jenkins; Christopher Petucci; Jeffrey A Culver; Bryan E Shepherd; Joshua P Fessel; Todd Hulgan; John R Koethe Journal: AIDS Res Hum Retroviruses Date: 2018-05-02 Impact factor: 2.205
Authors: Brian Kirmse; Tzy-Jyun Yao; Sean Hofherr; Deborah Kacanek; Paige L Williams; Charlotte V Hobbs; Rohan Hazra; William Borkowsky; Russell B Van Dyke; Marshall Summar Journal: AIDS Res Hum Retroviruses Date: 2016-01-19 Impact factor: 2.205